Plug-and-Play Technology

Electron Microscope Image of GEM particle
Electron Microscope Image of two GEM particles

Our proprietary technology exploits the innate and adaptive immune system to engage disease-causing pathogens at their port of entry, the mucosal layers of the body. Uniquely, our technology is build on particles that not only elicit a strong and robust systemic immune response, but also a strong local immune response in mucosal layers in the nose, airways, gut and other places in the body. The particles provide a safe and versatile backbone that can efficiently be loaded with a wide variety of antigens from viral, bacterial and parasitic pathogens, thereby mimicking the pathogenic entity.

15.11.11 Mucosis announces new scientific advisory board
more >

17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >

21.03.11 Mucosis starts clinical study with its lead product, Flugem®
more >

12.11.10 Dr. Barry Buckland joins the Mucosis supervisory board
more >

28.09.10 Mucosis B.V. and PATH sign agreement to pursue Mimopath®-based oral diarrhea vaccines
more >